Ozurdex, the first drug therapy for the treatment of macular oedema, following branch retinal vein
occlusion or central retinal vein occlusion, has been approved by the FDA.
A biological marker for neovascular age-related macular degeneration (AMD) has been discovered by a
team of researchers from the University of Kentucky.
CLEARVIEW Training has hosted the City University Pre-registration programme for the past 6 years.
This year delegates had the opportunity to run though full mock exams in all of the practical subjects, Ocular Disease Stations, Ocular Disease Vivas, The Routine Exam and the Contact Lens Exam. Additional lectures and workshops on the Clinical Decision Making Exam […]
Positive interim data results from the Phase II trial of OT-551 to treat geographic atrophy (GA), an
advanced form of AMD, have been announced by Othera Pharmaceuticals Inc.
Researchers at the Moran Eye Centre are using transmission electron microscopes (TEMs) to develop
TEM-compatible molecular probes with software that will tag cells with a molecular signature, creating ‘colour’ TEM
imaging.
Scientists at New York’s Rochester University say that playing violent video games may improve
contrast sensitivity, which is often impaired by amblyopia.
The premarket application for VisionCare Ophthalmic Technologies Inc’s implantable telescope for
end-stage AMD has been approved, with conditions, by the FDA in the US.
In what is believed to be the first comprehensive eye disease study among urban pre-schoolers,
investigators writing in the April issue of the journal Ophthalmology report that while vision problems are rare,
they are more common than once thought.
CET Quiz: Clinical Decision Making for Optometrists
June 1st, 2009 ~ 0 Comments
CET Quiz: Common Contact Lens Complications
May 19th, 2009 ~ 0 Comments
Drug therapy for macular oedema treatment approved
June 24th, 2009 ~ 0 Comments
AMD biological marker discovered
June 17th, 2009 ~ 0 Comments